Third quarter sales of $535.0 million beat analysts' average estimate of $508 million and represented 3 percent growth on a currency-neutral basis.
Investigators used gene expression and immunological profiling to detect distinct immune responses in dengue virus-infected children with or without symptoms.
The researchers described gut microbial diversity and composition differences in metastatic melanoma patients who did or did not respond to immunotherapy.
Announced during the company's recent analyst day, the instrument could mark a major step in mass spectrometry's ongoing move into clinical applications.
Amoy will supply its CD95 IHC and CpG2 qPCR kits to develop a companion diagnostic for Canbridge's lead product targeting recurrent glioblastoma multiforme.
The company's diagnostics business saw 8 percent growth, while its Covance segment retreated 2 percent. The firm lowered its adjusted EPS estimate for the full year.
The firm also plans to list its cardiac troponin I assay as CE marked and plans to submit data to the FDA for clearance of its Clarity system and assay in 2018.
Singulex's CEO provided an update at the JP Morgan Healthcare conference on the firm's progress in developing its immunodiagnostics platform.
Translational scientist Jacqueline Achkar of Albert Einstein Medical College will lead several collaborations to build a point-of-care diagnostic platform.
The firm will develop a platform to detect toxic algal blooms in freshwater and marine environments using its Array System and LightDeck technology.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.